Nutriband Inc. (NTRB)
NASDAQ: NTRB · Real-Time Price · USD
5.80
+0.07 (1.18%)
May 14, 2025, 10:11 AM - Market open
Company Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products.
The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products.
The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Nutriband Inc.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Gareth Sheridan |
Contact Details
Address: 121 South Orange Avenue, Suite 1500 Orlando, Florida 32801 United States | |
| Phone | 407 377 6695 |
| Website | nutriband.com |
Stock Details
| Ticker Symbol | NTRB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | February - January |
| Reporting Currency | USD |
| CIK Code | 0001676047 |
| CUSIP Number | 67092M208 |
| ISIN Number | US67092M2089 |
| Employer ID | 81-1118176 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Gareth Sheridan | Founder, Chief Executive Officer and Director |
| Serguei Melnik | Founder, President, Company Secretary and Executive Chairman of the Board |
| Gerald Goodman | Chief Financial Officer and Chief Accounting Officer |
| Dr. Alan Smith Ph.D. | Chief Operating Officer and President of 4P Therapeutics |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer |
| Michael Myer | President of Pocono Pharmaceutical |
| Tyler Overk | Head of Active Intelligence |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 10-K/A | [Amend] Annual report |
| Apr 28, 2025 | 10-K | Annual Report |
| Apr 9, 2025 | 8-K | Current Report |
| Mar 13, 2025 | SCHEDULE 13D | Filing |
| Mar 13, 2025 | SCHEDULE 13D | Filing |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 12, 2025 | 8-K | Current Report |
| Jan 29, 2025 | 8-K | Current Report |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 16, 2024 | DEF 14A | Other definitive proxy statements |